# EDGAR Filing Document

**Accession Number:** 0000944809
**File Stem:** 0001193125-26-275818
**Filing Date:** 2026-6
**Character Count:** 6728
**Document Hash:** 7343c576cff1b55c625e11efa41dd906
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-275818.hdr.sgml**: 20260618

**ACCESSION NUMBER**: 0001193125-26-275818

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 9

**CONFORMED PERIOD OF REPORT**: 20260618

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260618

**DATE AS OF CHANGE**: 20260618

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OPKO HEALTH, INC.
- **CENTRAL INDEX KEY:** 0000944809
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 752402409
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33528
- **FILM NUMBER:** 261102538

**BUSINESS ADDRESS:**
- **STREET 1:** 4400 BISCAYNE BLVD.
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33137
- **BUSINESS PHONE:** 305-575-4181

**MAIL ADDRESS:**
- **STREET 1:** 4400 BISCAYNE BLVD.
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33137

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Opko Health, Inc.
- **DATE OF NAME CHANGE:** 20070621

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** eXegenics Inc
- **DATE OF NAME CHANGE:** 20040505

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EXEGENICS INC
- **DATE OF NAME CHANGE:** 20011114

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** June 18, 2026<br>

------

OPKO Health, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-33528 | 75-2402409 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 4400 Biscayne Blvd. |  |  |
| Miami**,** Florida |  | 33137 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 305 575-4100<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock | OPK | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 18, 2026, OPKO Health, Inc. (the "<u>Company</u>") held its 2026 Annual Meeting of Stockholders (the "<u>Annual Meeting</u>"). Below is a summary of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting and the corresponding votes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. All eleven nominees were elected to the Board of Directors with each director receiving votes as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| Election of Directors | For | Against | Abstain | Broker Non-Votes |
| Phillip Frost, M.D. | 423666978 | 40175942 | 296243 | 79767645 |
| Jane H. Hsiao, Ph.D. | 422928151 | 40947325 | 263687 | 79767645 |
| Elias A. Zerhouni, M.D. | 420402573 | 42561617 | 1174973 | 79767645 |
| Steven D. Rubin | 409356877 | 54519219 | 263067 | 79767645 |
| Gary J. Nabel, M.D., Ph.D. | 420083341 | 43643796 | 412026 | 79767645 |
| Prem A. Lachman, M.D. | 428600587 | 35002548 | 536028 | 79767645 |
| Roger J. Medel, M.D. | 428125427 | 35411814 | 601922 | 79767645 |
| John A. Paganelli | 398032505 | 65734019 | 372639 | 79767645 |
| Richard C. Pfenniger, Jr. | 424416857 | 39352175 | 370131 | 79767645 |
| Subbarao V. Uppaluri, Ph.D. | 454992813 | 8481656 | 664694 | 79767645 |
| Alice Lin-Tsing Yu, M.D., Ph.D. | 418457740 | 45287103 | 394320 | 79767645 |

---

&nbsp;&nbsp;&nbsp;&nbsp;2. The stockholders voted to approve the Company's 2026 Equity Incentive Plan as disclosed in the Company's 2026 Proxy Statement for the Annual Meeting. The votes on this proposal were as follows:

---

| | | | |
|:---|:---|:---|:---|
| For | Against | Abstain | Broker Non-Votes |
| 440,096,997 | 23,694,041  | 348,125  | 79,767,645  |

---

&nbsp;&nbsp;&nbsp;&nbsp;3. The stockholders voted to approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company as disclosed in the Company's 2026 Proxy Statement for the Annual Meeting. The votes on this proposal were as follows:

---

| | | | |
|:---|:---|:---|:---|
| For | Against | Abstain | Broker Non-Votes |
| 446,238,170 | 17,487,326 | 413,667  | 79,767,645 |

---

&nbsp;&nbsp;&nbsp;&nbsp;4. The stockholders voted to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes on this proposal were as follows:

---

| | | |
|:---|:---|:---|
| For | Against | Abstain |
| 535,070,921 | 6,120,699  | 2,715,188  |

---

There were no broker non-votes for the proposal.

No other matters were considered or voted upon at the meeting.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | OPKO Health, Inc. |
| Date: | June 18, 2026 | By:  | /s/ Steven D. Rubin |
|  |  | Name: | Steven D. Rubin |
|  |  | Title: | Executive Vice President - Administration |

---

------